RECURSION PHARMACEUTICALS, INC.
RXRXNasdaq
$2.95
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↓ -45.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.6B
Enterprise Value
$920.8M
P/E
—
P/S
23.5
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-20.9%
Dividend Yield
—
Revenue (TTM)
$66.4M
Net Income (TTM)
-$559.8M
Free Cash Flow (TTM)
-$325.8M
Gross Margin
—
Operating Margin
-881.3%
Net Margin
-842.9%
ROE
-54.6%
ROIC
-119.5%
Debt / Equity
0.0
Net Cash
$638.0M
Return 1Y
-46.7%
Company profile
Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
- CEO
- Chistopher C. Gibson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 400
- Headquarters
- Utah
- Website
- recursion.com
Management & directors
- Taylor Ben RChief Financial Officer
- Khan NajatChief R&D Commercial Officer
- Hallett DavidChief Scientific Officer
- Gibson ChristopherChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
RXRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.5M↓ -56.1%
Diluted EPS-$0.22↓ -56.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.0M | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$84.6M | -$182.8M | -$245.7M | -$350.1M | -$479.0M | -$648.1M |
| Net income | -$87.0M | -$186.5M | -$239.5M | -$328.1M | -$463.7M | -$644.8M |
| Diluted EPS | -$3.99 | -$1.49 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| Operating cash flow | -$45.4M | -$158.6M | -$83.5M | -$287.8M | -$359.2M | -$371.8M |
| Free cash flow | -$51.2M | -$198.4M | -$120.6M | -$299.7M | -$372.9M | -$378.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -2135.7% | -1795.8% | -616.7% | -785.3% | -814.1% | -867.9% |
| Net margin | -2196.0% | -1832.2% | -601.0% | -736.0% | -788.0% | -863.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.4M | $26.1M | $4.5M | $14.7M | $19.2M | $5.2M | $35.5M | $6.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$100.5M | -$98.4M | -$183.8M | -$191.4M | -$176.2M | -$172.2M | -$108.3M | -$128.5M |
| Net income | -$97.5M | -$95.8M | -$178.9M | -$202.5M | -$171.9M | -$162.3M | -$108.1M | -$117.5M |
| Diluted EPS | -$0.40 | -$0.34 | -$0.56 | -$0.50 | -$0.41 | -$0.36 | -$0.17 | -$0.22 |
| Operating cash flow | -$82.2M | -$59.2M | -$115.4M | -$132.0M | -$76.4M | -$117.4M | -$46.1M | -$81.1M |
| Free cash flow | -$83.4M | -$63.8M | -$116.7M | -$133.8M | -$79.6M | -$117.6M | -$47.3M | -$81.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -697.4% | -377.1% | -4042.4% | -1297.9% | -916.8% | -3327.6% | -304.8% | -1985.6% |
| Net margin | -676.6% | -367.5% | -3935.5% | -1373.3% | -894.2% | -3135.3% | -304.2% | -1815.6% |
Company news
Jul 14, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Borgeson Blake | Sale | 40,000 | $3.96 | $158,500.00 | filing |
| 2026-07-01 | Dar Zavain | Award | 5,109 | $0.00 | $0.00 | filing |
| 2026-07-01 | Li Dean Y | Award | 3,747 | $0.00 | $0.00 | filing |
| 2026-06-18 | Bumpus Namandje | Sale | 3,963 | $3.18 | $12,602.34 | filing |
| 2026-06-17 | Borgeson Blake | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-17 | HERSHBERG ROBERT | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-17 | Michor Franziska | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-17 | Sun Elaine D | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-17 | Dar Zavain | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-17 | Li Dean Y | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-17 | Bumpus Namandje | Award | 88,424 | $0.00 | $0.00 | filing |
| 2026-06-15 | Taylor Ben R· Chief Financial Officer | Tax withholding | 5,396 | $3.15 | $16,997.40 | filing |
| 2026-06-05 | Gibson Christopher | Sale | 40,000 | $3.62 | $144,800.00 | filing |
| 2026-06-05 | Khan Najat· CEO and President | Sale | 23,588 | $3.58 | $84,459.19 | filing |
| 2026-06-05 | Gibson Christopher | C | 40,000 | $0.00 | $0.00 | filing |
| 2026-06-03 | Bumpus Namandje | Sale | 4,386 | $3.54 | $15,526.44 | filing |
| 2026-06-02 | Borgeson Blake | Sale | 30,000 | $3.68 | $110,400.00 | filing |
| 2026-05-22 | Gibson Christopher | Sale | 40,000 | $3.08 | $123,200.00 | filing |
| 2026-05-22 | Gibson Christopher | C | 40,000 | $0.00 | $0.00 | filing |
| 2026-05-15 | Khan Najat· CEO and President | Tax withholding | 62,701 | $3.04 | $190,611.04 | filing |
| 2026-05-15 | Hallett David· Chief Scientific Officer | Tax withholding | 26,657 | $3.04 | $81,037.28 | filing |
| 2026-05-15 | Taylor Ben R· Chief Financial Officer | Tax withholding | 25,018 | $3.04 | $76,054.72 | filing |
| 2026-05-15 | Gibson Christopher | Tax withholding | 22,821 | $3.04 | $69,375.84 | filing |
| 2026-05-07 | Gibson Christopher | Sale | 40,000 | $3.37 | $134,800.00 | filing |
| 2026-05-07 | Gibson Christopher | C | 60,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.